Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications.
The successful development of a mucosal vaccine depends critically on the use of a safe and effective immunostimulant and/or carrier system. This review describes the effectiveness and mode of action of an immunostimulating particle, derived from bacteria, used in mucosal subunit vaccines. The non-living particles, designated bacterium-like particles are based on the food-grade bacterium Lactococcus lactis. The focus of the overview is on the development of intranasal BLP-based vaccines to prevent diseases caused by influenza and respiratory syncytial virus, and includes a selection of Phase I clinical data for the intranasal FluGEM vaccine.
Mucosis BV , Groningen , Netherlands.
Natalija
N
Van Braeckel-Budimir
Bert Jan
BJ
Haijema
Kees
K
Leenhouts
Lactococcus lactis; RSV vaccines; carrier-adjuvant; influenza vaccines; mucosal vaccine technology; particles